Aptevo Therapeutics Inc., a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn. The company's marketed products also comprise HepaGam B used for the prevention of hepatitis-B recurrence following liver transplantation in HBsAg-positive liver transplant patients, and for the treatment following exposure to hepatitis-B; and VARIZIG for use in treating following exposure to varicella zoster virus, which causes chickenpox in high-risk individuals. Its investigational stage product candidates include MOR209/ES414, a bispecific immunotherapeutic protein that is in Phase I clinical trial for metastatic castration-resistant prostate cancer; ES210, a bispecific protein therapeutic that is in pre-clinical development stage for inflammatory bowel diseases; otlertuzumab, a monospecific protein therapeutic that is in Phase II clinical trial for chronic lymphocytic leukemia; ROR1, a bispecific immunotherapeutic protein that is in preclinical development; APVO436, a bispecific protein therapeutic, which is in pre-clinical development; and other therapeutic protein product candidates for cancer. The company was incorporated in 2016 and is based in Seattle, Washington.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:APVO
CUSIPN/A
Phone206-838-0500
Debt
Debt-to-Equity Ratio0.27
Current Ratio3.66
Quick Ratio3.50
Price-To-Earnings
Trailing P/E Ratio-2.48
Forward P/E Ratio-1.58
P/E GrowthN/A
Sales & Book Value
Annual Sales$14.66 million
Price / Sales5.88
Cash FlowN/A
Price / CashN/A
Book Value$3.83 per share
Price / Book0.99
Profitability
EPS (Most Recent Fiscal Year)($1.53)
Net Income$6.97 million
Net Margins74.01%
Return on Equity-45.53%
Return on Assets-30.83%
Miscellaneous
Employees121
Outstanding Shares22,670,000
Market Cap$91.13 million
Aptevo Therapeutics (NASDAQ:APVO) Frequently Asked Questions
What is Aptevo Therapeutics' stock symbol?
Aptevo Therapeutics trades on the NASDAQ under the ticker symbol "APVO."
How were Aptevo Therapeutics' earnings last quarter?
Aptevo Therapeutics Inc (NASDAQ:APVO) issued its quarterly earnings data on Thursday, August, 9th. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.65) by $0.07. The biotechnology company had revenue of $6.83 million for the quarter, compared to the consensus estimate of $4.17 million. Aptevo Therapeutics had a net margin of 74.01% and a negative return on equity of 45.53%. View Aptevo Therapeutics' Earnings History.
When is Aptevo Therapeutics' next earnings date?
What price target have analysts set for APVO?
2 brokers have issued 12 month price targets for Aptevo Therapeutics' stock. Their predictions range from $11.00 to $12.00. On average, they expect Aptevo Therapeutics' stock price to reach $11.50 in the next year. This suggests a possible upside of 202.6% from the stock's current price. View Analyst Price Targets for Aptevo Therapeutics.
What is the consensus analysts' recommendation for Aptevo Therapeutics?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptevo Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aptevo Therapeutics.
Who are some of Aptevo Therapeutics' key competitors?
Some companies that are related to Aptevo Therapeutics include Aquestive Therapeutics (AQST), Verrica Pharmaceuticals (VRCA), Evolus (EOLS), American Brivision (Holding) (ABVC), Synergy Pharmaceuticals (SGYP), Eidos Therapeutics (EIDX), Concert Pharmaceuticals (CNCE), Kalvista Pharmaceuticals (KALV), Catalyst Pharmaceuticals (CPRX), resTORbio (TORC), Savara (SVRA), Magenta Therapeutics (MGTA), Albireo Pharma (ALBO), Neptune Wellness Solutions (NEPT) and Avid Bioservices (CDMO).
Who are Aptevo Therapeutics' key executives?
Aptevo Therapeutics' management team includes the folowing people:
- Mr. Marvin L. White, Pres, CEO & Director (Age 56)
- Mr. Jeffrey G. Lamothe, Sr. VP, CFO & Treasurer (Age 52)
- Dr. Scott C. Stromatt, Sr. VP of Clinical Devel. & Medical Affairs and Chief Medical Officer (Age 60)
- Mr. Randy Joe Maddux, Sr. VP of Operations & Chief Manufacturing Officer (Age 57)
- Dr. Jane A. Gross, Sr. VP & Chief Scientific Officer (Age 61)
How do I buy shares of Aptevo Therapeutics?
Shares of APVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aptevo Therapeutics' stock price today?
One share of APVO stock can currently be purchased for approximately $3.80.
How big of a company is Aptevo Therapeutics?
Aptevo Therapeutics has a market capitalization of $91.13 million and generates $14.66 million in revenue each year. The biotechnology company earns $6.97 million in net income (profit) each year or ($1.53) on an earnings per share basis. Aptevo Therapeutics employs 121 workers across the globe.
What is Aptevo Therapeutics' official website?
How can I contact Aptevo Therapeutics?
Aptevo Therapeutics' mailing address is 2401 4TH AVENUE SUITE 1050, SEATTLE WA, 98121. The biotechnology company can be reached via phone at 206-838-0500 or via email at [email protected]
MarketBeat Community Rating for Aptevo Therapeutics (NASDAQ APVO)
MarketBeat's community ratings are surveys of what our community members think about Aptevo Therapeutics and other stocks. Vote "Outperform" if you believe APVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APVO will underperform the S&P 500 over the long term. You may vote once every thirty days.
